Headlines

Johnson & Johnson (JNJ) says on track to become first healthcare company to exceed USD 100bln in annual revenue, with a clear line of sight to double-digit growth by the end of the decade

Newsquawk Staff ·

  • Executive says expects to elevate free cash flow generation to approximately USD 21bln in 2026.

What it means

Johnson & Johnson's guidance to surpass USD 100 billion in annual revenue could signal strong growth prospects, especially with a projected boost in free cash flow to USD 21 billion by 2026. This outlook may enhance investor confidence in the stock, positioning it favorably in the pharmaceutical space and potentially impacting sector dynamics as a notable trendsetter.

Related headlines